Cilta-Cel May Fulfill Unmet Need for Multiple Myeloma Patients in China
Ciltacabtagene autoleucel had a favorable risk-benefit profile in a study of Chinese patients with relapsed/refractory multiple myeloma, according to researchers.
CAR-T Therapy
Outcomes After Relapse, Nonresponse to Tisagenlecleucel in B-ALL
Patients with B-ALL who do not respond to tisagenlecleucel have worse overall survival than patients who relapse after tisagenlecleucel treatment.
GPRC5D May Be Promising New Target for CAR T-Cell Therapy in Multiple Myeloma
GPRC5D-targeted CAR T-cell therapy may be a promising treatment for heavily pretreated multiple myeloma, a phase 1 trial suggests.
Tisagenlecleucel Plus Pembrolizumab May Be Effective in R/R DLBCL
Tisagenlecleucel plus pembrolizumab produced responses in patients with relapsed/refractory diffuse large B-cell lymphoma.
Response to Axicabtagene Ciloleucel Superior to Standard Care in R/R Large B-Cell Lymphoma
Axi-cel improved event-free survival vs standard care in older patients with relapsed/refractory large B-cell lymphoma.
First-Line Axi-Cel Appears Effective in High-Risk Large B-Cell Lymphoma
At a median follow-up of 15.9 months, the median duration of response was not reached.
Smartphone App Helps Guide Use of CAR T-Cell, BiTE Therapy
The “myTcell” app is expected to be released in the United States in 2022.
Anakinra Can Prevent Severe CRS, ICANS After CAR T-Cell Therapy
There was 1 case of grade 3 CRS and 1 case of grade 4 CRS.
Brexu-Cel Deemed Safe, Effective for Mantle Cell Lymphoma in Real-World Study
Outcomes were similar to those seen in the ZUMA-2 trial.
Hospitalization, ED Visits Highest in First Month After CAR T-Cell Infusion
Sixty-seven percent of rehospitalizations occurred within the first month of CAR T-cell infusion.
- Loading...
Loading...
Next post in ASH 2021 CAR-T In-depth
Loading... 
Loading...